Allogeneic ABCB5-positive Limbal Stem Cells
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03549299)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03549299 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2018 | FGK Clinical Research GmbH, Granzer Regulatory Consulting & Services, Rheacell GmbH & Co. KG, TICEBA GmbH, University of Heidelberg |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2018 |
| Granzer Regulatory Consulting & Services | For profit | 1 | 0 | 1 | 2018 |
| Rheacell GmbH & Co. KG | For profit | 1 | 1 | 1 | 2018 |
| TICEBA GmbH | For profit | 1 | 0 | 1 | 2018 |
| University of Heidelberg | Academic/Hospital | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1